TORONTO, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it will submit the Type C meeting request package to the U.S. Food & Drug Administration (“FDA”) by mid-December 2022, which will outline the overall development plan and Pre-Dose selection data supporting the latest revised endpoints for the Company’s Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. Following the submission of the Type C meeting request package, the Company expects to hear from the FDA on a firm date for the meeting.
See the original post:
Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the...
Related Post
- Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer - November 27th, 2024
- Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference - November 27th, 2024
- Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference - November 27th, 2024
- Fate Therapeutics to Present at Upcoming December Investor Conferences - November 27th, 2024
- Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference - November 27th, 2024
- 89bio to Participate in the 7th Annual Evercore HealthCONx Conference - November 27th, 2024
- Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024 - November 27th, 2024
- Fulcrum Therapeutics to Participate in Upcoming December Conferences - November 27th, 2024
- Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference - November 27th, 2024
- PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024 - November 27th, 2024
- Lifecore Biomedical Amends and Extends Revolving Credit Facility with BMO - November 27th, 2024
- Fortrea to Present at the Citi Global Healthcare Conference - November 27th, 2024
- NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel - November 27th, 2024
- Fortrea to Present at the Evercore HealthCONx Conference - November 27th, 2024
- ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference - November 27th, 2024
- Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - November 27th, 2024
- Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference - November 27th, 2024
- Idorsia enters into exclusive negotiations for global rights to aprocitentan - November 27th, 2024
- Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of... - November 27th, 2024
- 142,701 Orion Corporation A shares converted into B shares - November 27th, 2024
- Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant... - November 3rd, 2024
- Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024 - November 3rd, 2024
- Skye Bioscience to Announce Third Quarter 2024 Results - November 3rd, 2024
- Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - November 3rd, 2024
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 3rd, 2024
- Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024 - November 3rd, 2024
- TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update - November 3rd, 2024
- Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial - November 3rd, 2024
- Galecto Reports Third Quarter 2024 Financial Results - November 3rd, 2024
- Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024 - November 3rd, 2024
- Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results - November 3rd, 2024
- Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data - November 3rd, 2024
- Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and... - November 3rd, 2024
- Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - November 3rd, 2024
- Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on... - November 3rd, 2024
- Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP) - November 3rd, 2024
- Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - November 3rd, 2024
- Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes - November 3rd, 2024
- NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update - November 3rd, 2024
- ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer... - November 3rd, 2024
- Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting - October 6th, 2024
- Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024 - October 6th, 2024
- Umoja Biopharma Announces Poster Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer - October 6th, 2024
- Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - October 6th, 2024
- BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting - October 6th, 2024
- Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 - October 6th, 2024
- NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting - October 6th, 2024
- TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting - October 6th, 2024
- Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress - October 6th, 2024
- Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - October 6th, 2024
- Major Shareholder Announcement - October 6th, 2024
- Altamira Therapeutics Provides Update on Nasdaq Listing - October 6th, 2024
- Trevena Announces Receipt of Nasdaq Delisting Notification - October 6th, 2024
- Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant - October 6th, 2024
- Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - October 6th, 2024
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 6th, 2024
- Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - October 6th, 2024
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - October 6th, 2024
- OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million - October 6th, 2024
- Sabin Vaccine Institute Delivers Marburg Vaccines to Combat Outbreak in Rwanda - October 6th, 2024
- Celldex Therapeutics to Present at Upcoming Investor Conferences - September 13th, 2024
- NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences - September 13th, 2024
- Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - September 13th, 2024
- One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations - September 13th, 2024
- Tilray Brands Completes Acquisition of Atwater Brewery From Molson Coors Beverage Company - September 13th, 2024
- Generation Bio to Present at the 2024 Cantor Global Healthcare Conference - September 13th, 2024
- QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil’s national screening programs - September 13th, 2024
- Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388 - September 13th, 2024
- Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in... - September 13th, 2024
- Immunocore to present at the 2024 Cantor Global Healthcare Conference - September 13th, 2024
- Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros - September 13th, 2024
- Lifecore Biomedical to Participate in Craig-Hallum Bioprocessing Conference - September 13th, 2024
- Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference - September 13th, 2024
- BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC - September 13th, 2024
- XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A - September 13th, 2024
- Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference - September 13th, 2024
- MBX Biosciences Announces Pricing of Initial Public Offering - September 13th, 2024
- FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy - September 13th, 2024
- Valneva Announces the Success of its Private Placement Raising approximately €60 Million - September 13th, 2024
- Nxera’s Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO - September 13th, 2024